Topical Delivery of ROS-Responsive Methotrexate Prodrug Nanoassemblies by a Dissolvable Microneedle Patch for Psoriasis Therapy
DOI: https://doi.org/10.2147/IJN.S394957
IF: 7.033
2023-02-19
International Journal of Nanomedicine
Abstract:Yong Zhou, 1, &ast Lei Yang, 1, &ast Yifu Lyu, 1, &ast Di Wu, 1 Ying Zhu, 1 Jingjing Li, 1 Dabo Jiang, 1 Xiaofei Xin, 1 Lifang Yin 1– 4 1 Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China; 2 NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, China, Nanjing, People's Republic of China; 3 Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Nanjing, People's Republic of China; 4 State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lifang Yin; Xiaofei Xin, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China, Tel +86 (025)83271018, Email ; Purpose: Oxidative stress, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and adenosine signaling are factors associated with psoriatic inflammation. Topical delivery of methotrexate (MTX) has become an option to overcome the side effects caused by systemic therapy in psoriasis, leading to the suppression of NF-κB activation through boosting adenosine release. However, thickened psoriatic skin is the primary restriction against local drug delivery. Methods: In this study, a ROS responsive MTX prodrug (MTX-TK-HA) was synthesized with the feature of CD44 mediated active targeting to hyperproliferative keratinocytes. MTX prodrug and PLA-mPEG were formulated by nano-precipitation method to develop the MTX-TK-HA/PLA-mPEG nanoassemblies. To achieve painless transdermal delivery, a dissolving microneedle was applied for direct loading of these nanoassemblies by micromolding technique. The particle size, zeta potential, ROS-responsiveness, permeability, and mechanical strength of nanoassemblies and microneedle arrays were determined, respectively. Then, MTT assay, immunoblot analysis, ELISA assay, flow cytometry, and histological staining were utilized to thoroughly evaluate the efficacy of nanoassemblies-loaded microneedles in an imiquimod-induced psoriatic mouse model. Results: Nanoassemblies-loaded microneedle arrays were capable of significantly penetrating imiquimod-induced psoriatic epidermis in mice. The efficient topical delivery of these nanoassemblies was achieved by potent mechanical strength and hyaluronic acid as the dissolvable matrix for microneedle arrays. CD44-mediated endocytosis enabled the intracellular uptake of nanoassemblies in keratinocytes, and methotrexate was released from MTX-TK-HA with ROS stimuli, followed by suppressing the proliferation of epidermal cells via NF-κB pathway blockade. Conclusion: In a psoriatic mouse model, nanoassemblies loaded microneedle arrays relieve inflammatory skin disorders via regulation of adenosine and NF-κB signaling. Our study offered a rational design for the transdermal delivery of hydrophobic agents and defined an effective therapeutic option for psoriasis treatment. Keywords: psoriasis, ROS-responsiveness, microneedle, topical delivery, methotrexate Psoriasis is a chronic auto-inflammatory skin disease followed by prolonged action of oxidative stress, hyperproliferative keratinocytes, and inflamed skin with scaly patches. 1,2 Excessive oxidative stress in psoriatic skin lesions associates with proinflammatory cytokine production via the intracellular kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase signaling (MAPK) signaling pathway. 3 Due to these features, keratinocytes undergo aberrant proliferation and transduce exogenous environmental stimuli for the initiation and perpetuation of cutaneous inflammation. 4,5 Both topical and systemic retinoids, vitamin D and ciclosporin, are utilized in psoriasis treatment. 6 However, concomitant severe side effects including increased risk of coronary heart disease, toxicity and cancer are associated with retinoids and immune drug-based therapies. 7 Regulation of adenosine release is a promising therapeutic strategy for psoriasis patients. 8,9 Methotrexate (MTX) with modulation of adenosine signaling, anti-proliferative and anti-inflammatory functions, is the first systemic drug of choice for moderate-to-severe psoriatic patients with few side effects but short half-life of 3–10 h. 10,11 Keratinocytes from lesional epidermis exhibited overall 2.9-fold increase of CD44 expression in psoriasis, compared to nonlesional epidermis, which could serve as the active target for nanocarri -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology